Insights & news

Polish Competition Authority Takes Enforcement Action in Pharmaceutical Sector (Wholesalers and Medical Gases)

  • 20/11/2020
  • Articles

The Polish competition authority, the Office of Competition and Consumer Protection (UOKiK), has proven to be an energetic enforcer of the competition rules. Over the past few days, UOKiK found itself in the limelight because of two new distinct inquiries in the pharmaceutical sector that target pharmaceutical wholesalers and suppliers of medical gases (see, attached UOKiK press releases of 19 and 17 November 2020).
 
Pharmaceutical wholesalers
 
In September 2020, UOKiK officials carried out surprise inspections at the premises of both pharmaceutical wholesalers and software suppliers, six in total. These parties stand accused of having exchanged business-sensitive information, including medicine prices, while relying on specific software that allowed for the review of competing wholesale prices. The practices are allegedly in breach of Polish and EU competition law. 
 
Medical gases 
 
The President of UOKiK announced the start of an inquiry into the supply of medical gases, especially oxygen, to hospitals. Oxygen plays an important part in the treatment of patients afflicted with Covid-19. The Polish hospital market for medical gases is highly concentrated with the four largest players having an aggregate market share in excess of 90%. UOKiK will probe that market for possible foreclosure resulting from unilateral abusive conduct or multilateral collusive behaviour. The objective of UOKiK is to guarantee market access for all suppliers, including the smaller players, and thus ensure the uninterrupted supply of medical gases to hospitals and their patients. In this context, market access also implies the ability for newcomers  to use the systems, logistics and infrastructure already in place in the hospital for the delivery and administration of the gases.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 27/11/2020
    • Articles

    European Commission Fines Cephalon and Teva On Account of "Pay-for-Delay" Patent Settlement Agreement

    On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine (see, attached Commission press release).

    Read more
    • 26/11/2020
    • Articles

    European Commission Presents Pharmaceutical Strategy for Europe

    On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020).

    Read more
    • 25/11/2020
    • Articles

    Potential Covid-19 Vaccine Supplier Moderna Sixth Contract Partner of European Commission

    On 24 November 2020, European Commission President von der Leyen released a statement announcing that she would approve a sixth agreement with a supplier of a potential Covid-19 vaccine (see, attachment). The Commission’s new contract partner is Moderna. Under the agreement, the Commission will have the right to buy up to 160 million doses of the vaccine, if and when that product obtains a marketing authorisation from the European Medicines Agency. In recent days, the Commission announced similar deals with CureVac (see, Van Bael & Bellis Life Sciences News Alert of 17 November 2020) and with BioNTech and Pfizer (see, Van Bael & Bellis Life Sciences News Alert of 12 November 2020). The Commission President suggested that a seventh agreement is being negotiated which paves the way for the creation in Europe of “one of the most comprehensive COVID-19 vaccine portfolios in the world”.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *